Narrative review explores oncolytic viral therapy for pancreatic cancer, suggesting new targeted therapies are emerging.
Pancreatic cancer (PC) remains one of the most formidable malignancies, with survival rates showing minimal improvement over the years despite progress in chemotherapy, targeted treatments, and radiation therapy. The development of targeted agents and chemotherapy for cancer treatment has only moderately influenced clinical results and has not significantly altered 5-year survival rates. However, with the rapid discovery of the genetic and molecular functions underlying PC, new opportunities for targeted therapies are emerging. One promising approach is oncolytic viral therapy, which has shown potential as a targeted agent for the treatment of pancreatic cancer. Based on the available evidence, oncolytic viral therapy appears to be a viable treatment option for pancreatic cancer. In the present narrative review, we explore oncolytic viruses in detail, and their potential applications in cancer therapy as a future alternative treatment are investigated.
No takes yet. Share an insight, caveat, or question.
Shadbash et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: